This page contains details about ViiV Healthcare clinical trials. Approved prescribing information must continue to guide appropriate use of ViiV Healthcare medicines. This information may vary from country to country. Before prescribing any product mentioned in this section, Healthcare Professionals should consult prescribing information approved in their country.
Use the filters below to find out more about ViiV Healthcare clinical trials for dolutegravir/lamivudine, cabotegravir▼ & rilpivirine▼, fostemsavir▼ and dolutegravir/rilpivirine▼.
Showing results for
NP-GBL-HVX-WCNT-220013 April 2022
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221441.
If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.
